Drugs / Basimglurant
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT02433093 | Apr → Sep 2015 | major depressive disorder | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01873508 | Jun → Aug 2013 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01665404 | Jul → Sep 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01629368 | Jun → Sep 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01592890 | Apr → May 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01483469 | Dec 2011 → Oct 2013 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01368926 | Jun → Nov 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01045083 | Jan 2010 → Jun 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT05059327 | Mar 2022 → Feb 2025 | tuberous sclerosis | Noema Pharma AG | Completed | No outcome recorded |
| Phase 2 | NCT01750957 | Feb 2013 → Apr 2014 | fragile X syndrome | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01517698 | May 2012 → Apr 2014 | fragile X syndrome | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01437657 | Oct 2011 → Sep 2013 | major depressive disorder | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01015430 | Nov 2009 → Jan 2011 | fragile X syndrome | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00809562 | Mar 2009 → Feb 2011 | depressive disorder | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05217628 | Jan 2022 → Feb 2027 expected | trigeminal neuralgia | Noema Pharma AG | Active not recruiting | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Basimglurant | “Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression:” PMID 27304433 ↗ Jul 2016 |
| Known as | NOE-101 | “The study drug (NOE-101, basimglurant) is a potent inhibitor of metabotropic glutamate receptor 5 (mGluR5)” NCT05059327 ↗1“NOE-101” NCT05217628 ↗ |
| Known as | RG-7090 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301626 ↗ |
| Known as | RO4917523 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01665404 ↗ |
| Known as | RO4917523-000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301626 ↗ |
| Known as | RO4917523-009 SULPHATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301626 ↗ |
| Action | Inhibit | “Antagonism of the postsynaptic metabotropic glutamate subtype 5 receptor” PMID 27304433 ↗ Jul 2016 |
| Modality | Small molecule | — CHEMBL3301626 ↗ |
| Route | Oral | “daily oral RO4917523” NCT00809562 ↗ |
| Target | GRM5 | “Metabotropic glutamate receptor 5 modulator” CHEMBL3301626 ↗ |